BOTHELL, WA and VANCOUVER, May 27 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will hold a live webcast and conference call of presentations made at an OncoGenex hosted reception during the 2009 American Society of Clinical Oncology Annual Meeting (ASCO) on Saturday, May 30, 2009. The webcast will begin at 7:10 p.m. EDT.
During the reception, OncoGenex management and guest speakers will provide a comprehensive review of the final results of a randomized Phase 2 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, as well as discuss the treatment landscape and the relevance of clinical trial endpoints for prostate cancer.
Guest speakers include: Dr. Kim Chi, OGX-011 Principal Investigator, BC Cancer Agency Dr. Oliver Sartor, Medical Oncologist, Tulane Medical School Dr. Tomasz Beer, Medical Oncologist, Oregon Health & Science University Dr. Brent Blumenstein, Independent Statistician, Trial Architecture Consulting Dr. Martin Gleave, Distinguished Professor, Department of Urologic Sciences, University of British Columbia and Chief Scientific Officer, OncoGenex Pharmaceuticals, Inc.
To access the webcast, log on to the Investor Relations page of the OncoGenex Web site at www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-627-6544 (U.S. & Canada) or 719-325-4857 (International). A webcast replay will be available approximately two hours after the call and will be archived at www.oncogenex.com.
About OncoGenex Pharmaceuticals
OncoGenex Pharmaceuticals is a biopharmaceutical co
|SOURCE OncoGenex Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved